| Literature DB >> 26895682 |
Sunil Amin1, Michelle Kang Kim2.
Abstract
Islet cell tumors of the pancreas, also known as pancreatic neuroendocrine tumors, constitute less than 5% of pancreatic tumors, and 7% of all neuroendocrine tumors. Most are non-functional, and patients often present with metastatic disease. Functional tumors present with distinct clinical syndromes. Accurate staging is critical as surgery is both the cornerstone of treatment, and the only hope for cure. Medical management involves treating the manifestations of hormonal excess, and using somatastatin analogues when appropriate. Systemic chemotherapy, targeted molecular therapy, and peptide receptor radiotherapy may be used for refractory disease in lieu of or as an adjunct to surgery.Entities:
Keywords: Islet cell tumor; Pancreas; Pancreas cancer; Pancreatic neuroendocrine tumors (PNET); Targeted molecular therapy
Mesh:
Substances:
Year: 2016 PMID: 26895682 DOI: 10.1016/j.gtc.2015.10.007
Source DB: PubMed Journal: Gastroenterol Clin North Am ISSN: 0889-8553 Impact factor: 3.806